WASHINGTON (Reuters) – U.S. drug regulators may announce their decision allowing emergency use of Gilead Science Inc’s experimental coronavirus drug remdesivir as soon as Wednesday, the New York Times reported, citing an unnamed senior administration official.
Dr. Anthony Fauci, the nation’s top infectious disease official at the National Institutes of Health, earlier on Wednesday told reporters at the White House that initial data on the potential treatment looked promising but needed more review, adding that he had no timeline for the Food and Drug Administration’s approval.
Writing by Susan Heavey, Editing by Franklin Paul
Our Standards:The Thomson Reuters Trust Principles.
Subscribe to our Newsletter and get the complete health program for a health you.